US 11,780,844 B2
Compounds and methods for treatment of viral infections
Mark J. Bartlett, Castro Valley, CA (US); Daniel H. Byun, Foster City, CA (US); Yifan Deng, Milpitas, CA (US); Jennifer L. Cosman Ellis, Foster City, CA (US); Rao V. Kalla, Cupertino, CA (US); Richard L. Mackman, Millbrae, CA (US); Dustin S. Siegel, Half Moon Bay, CA (US); and Xianhuang Zeng, Redwood City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Mar. 6, 2023, as Appl. No. 18/117,858.
Application 18/117,858 is a continuation of application No. 18/115,955, filed on Mar. 1, 2023.
Claims priority of provisional application 63/434,993, filed on Dec. 23, 2022.
Claims priority of provisional application 63/424,083, filed on Nov. 9, 2022.
Claims priority of provisional application 63/390,421, filed on Jul. 19, 2022.
Claims priority of provisional application 63/315,769, filed on Mar. 2, 2022.
Prior Publication US 2023/0279013 A1, Sep. 7, 2023
Int. Cl. C07D 487/04 (2006.01); A61P 31/14 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 31/14 (2018.01)] 6 Claims
 
1. A compound of Formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.